SEARCH

SEARCH BY CITATION

References

  • 1
    Hamilton BE, Martin JA, Ventura SJ, Sutton PD, Menacker F. Births: preliminary data for 2004. Natl Vital Stat Rep 2005; 54: 117.
  • 2
    Mackenzie R, Walker M, Armson A, Hannah ME. Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol 2006; 194: 12341242.
  • 3
    Steer P. The epidemiology of preterm labour. BJOG 2005; 112: 13.
  • 4
    Saigal S, Stoskopf B, Streiner D, Boyle M, Pinelli J, Paneth N, Goddeeris J. Transition of extremely low-birth-weight infants from adolescence to young adulthood: comparison with normal birth-weight controls. JAMA 2006; 295: 667675.
  • 5
    Marlow N, Wolke D, Bracewell MA, Samara M, for the EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Eng J Med 2005; 352: 919.
  • 6
    Mercer BM. Preterm premature rupture of the membranes. Obstet Gynecol 2003; 101: 178193.
  • 7
    Mathews TJ, MacDorman MF. Infant mortality statistics from the 2004 period linked birth/infant death data set. Natl Vital Stat Rep 2007; 55: 132.
  • 8
    Kramer MS, Demissie K, Yang H, Platt RW, Sauvé R, Liston R, for the Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. JAMA 2000; 284: 843849.
  • 9
    Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR, for the EPICure Study Group. N Engl J Med 2000; 343: 378384.
  • 10
    Institute of Medicine. Report brief. July 2006. Preterm birth: causes, consequences, and prevention. http://www.iom. edu/Object.File/Master/35/975/pretermbirth.pdf [Accessed 14 March 2007].
  • 11
    Meis PJ, Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Miodovnik M, Menard MK, Caritis SN, Thurnau GR, Bottoms SF, Das A, Roberts JM, McNellis D, for the Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. The Preterm Prediction Study: risk factors for indicated preterm births. Am J Obstet Gynecol 1998; 178: 562567.
  • 12
    Chandiramani M, Shennan A. Preterm labour: update on prediction and prevention strategies. Curr Opin Obstet Gynecol 2006; 18: 618624.
  • 13
    Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev 2006; January 25; CD004947.
  • 14
    Keirse MJNC. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990; 97: 149154.
  • 15
    da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419424.
  • 16
    Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Maowad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 23792385.
  • 17
    Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994; 62: 485490.
  • 18
    De Ziegler D, Bulletti C, De Monstier B, Jääskeläinen A-S. The first uterine pass effect. Ann N Y Acad Sci 1997; 828: 291299.
  • 19
    Cicinelli E, De Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000; 95: 403406.
  • 20
    Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, Franceschetti F. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997; 12: 10731079.
  • 21
    Cicinelli E, Borraccino V, Petruzzi D, Mazzotta N, Cerundolo ML, Schönauer LM. Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 1996; 65: 860862.
  • 22
    Toner JP. Vaginal delivery of progesterone in donor oocyte therapy. Hum Reprod 2000; 15 (Suppl 1): 166171.
  • 23
    Shangold MM, Tomai TP, Cook JD, Jacobs SL, Zinaman MJ, Chin SY, Simon JA. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril 1991; 56: 10401047.
  • 24
    Murray JL. Natural progesterone: what role in women's health care? Women Health Primary Care 1998; 1: 671687.
  • 25
    Mahaguna V, McDermott JM, Zhang F, Ochoa F. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Phar 2004; 30: 10691078.
  • 26
    American College of Obstetricians and Gynecologists. ACOG Committee opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol 2003; 102: 11151116.
  • 27
    Iams JD. Supplemental progesterone to prevent preterm birth. Am J Obstet Gynecol 2003; 188: 303.
  • 28
    Yost NP, Owen J, Berghella V, MacPherson C, Swain M, Dildy GA III, Miodovnik M, Langer O, Sibai B, for the National Institute of Child Health and Human Development, Maternal-Fetal Medicine Units Network. Number and gestational age of prior preterm births does not modify the predictive value of a short cervix. Am J Obstet Gynecol 2004; 191: 241246.
  • 29
    To MS, Skentou C, Liao AW, Cacho A, Nicolaides KH. Cervical length and funneling at 23 weeks of gestation in the prediction of spontaneous early preterm delivery. Ultrasound Obstet Gynecol 2001; 18: 200203.
  • 30
    Crinone 4%/Crinone 8% (progesterone gel) prescribing information. Columbia Laboratories, Inc: Livingston, NJ, December 2006.
  • 31
    Prochieve 4%/Prochieve 8% (progesterone gel) prescribing information. Columbia Laboratories, Inc: Livingston, NJ, November 2004.
  • 32
    Iams JD, Goldenberg RL, Mercer BM, Moawad A, Thom E, Meis PJ, McNellis D, Caritis SN, Miodovnik M, Menard MK, Thurnau GR, Bottoms SE, Roberts JM, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The Preterm Prediction Study: recurrence risk of spontaneous preterm birth. Am J Obstet Gynecol 1998; 178: 10351040.
  • 33
    Gonik B, Creasy RK. Preterm labor: its diagnosis and management. Am J Obstet Gynecol 1986; 154: 38.
  • 34
    Toner JP. The luteal phase: luteal support protocols. In Textbook of Assisted Reproductive Techniques, GardnerDK, WeissmanA, HowlesCM, ShohamZ (eds). Martin Dunitz Ltd: London, 2004; 639650.
  • 35
    Christian MS, Brent RL, Calda P. Embryo-fetal toxicity signals for 17 alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins. J Matern Fetal Neonatal Med 2007; 20: 89112.
  • 36
    Ness A, Dias T, Damus K, Burd I, Berghella V. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol 2006; 195: 11741179.
  • 37
    Johnson JWC, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17α-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975; 293: 675680.
  • 38
    Hauth JC, Gilstrap LC III, Brekken AL, Hauth JM. The effect of 17α-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 1983; 146: 187190.
  • 39
    Hartikainen-Sorri A-L, Kauppila A, Tuimala R. Inefficacy of 17α-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980; 56: 692695.
  • 40
    Fuchs F, Stakemann G. Treatment of threatened premature labor with large doses of progesterone. Am J Obstet Gynecol 1960; 79: 172176.
  • 41
    Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989; 96: 265274.
  • 42
    Di Renzo GC, Rosati A, Mattei A, Gojnic M, Gerli S. The changing role of progesterone in preterm labour. BJOG 2005; 112: 5760.
  • 43
    Guaschino S, Ricci E, Franchi M, Frate GD, Tibaldi C, Santo DD, Ghezzi F, Benedetto C, Seta FD, Parazzini F. Treatment of asymptomatic bacterial vaginosis to prevent pre-term delivery: a randomised trial. Eur J Obstet Gynecol Reprod Biol 2003; 110: 149152.
  • 44
    Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, Heine RP, Nugent RP, Fischer ML, Leveno KJ, Wapner R, Varner M. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000; 342: 534540.
  • 45
    Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril 1998; 69: 96101.
  • 46
    Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 2000; 6: 139148.
  • 47
    Sexton DJ, O'Reilly MW, Friel AM, Morrison JJ. Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro. Reprod Biol Endocrinol 2004; 2: 80.
  • 48
    Food and Drug Administration. 17α-Alpha hydroxyprogesterone caproate for prevention of preterm birth: overview of FDA background document. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4227B1-02-01-FDA-Background.pdf [Accessed July 13, 2007].
  • 49
    Gonzalez-Quintero VH, Smarkusky L, Carter J, Istwan N, Rhea D. 17 Alpha-hydroxyprogesterone caproate: perinatal mortality and pregnancy outcomes. Obstet Gynecol 2007; 109 (Suppl): 1S2S.
  • 50
    Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007; 357: 462469.
  • 51
    Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, Thom E, McNellis D, Copper RL, Johnson F, Roberts JM. NICHD Maternal Fetal Medicine Unit Network. The length of the cervix and the risk for spontaneous premature delivery. N Engl J Med 1996; 334: 567572.
  • 52
    DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al. Vaginal progesterone is associated with a decrease in the risk for early preterm birth and improves neonatal outcome in women with a short cervix: a secondary analysis from a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 697705.
  • 53
    Kleinstein J, for the Luteal Phase Study Group. Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertil Steril 2005; 83: 16411649.